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Background: Even when promptly recognized and treated, aortoesophageal (AEF) and aortobronchial (ABF) fistulae are
highly lethal conditions. Open surgical repair also carries a high risk of mortality and morbidity. Several alternative
strategies have been recently reported in the literature including thoracic endovascular aortic repair (TEVAR). However,
relatively little is known about results of TEVAR for AEF and ABF due to their rarity and the lack of large surveys.
Methods: A voluntary national survey was conducted among Italian universities and hospital centers with an endovascular
program. Questionnaires were distributed by e-mail to participating centers and aimed to evaluate the results of
endovascular repair of established AEF or ABF.
Results: Seventeen centers agreed to participate and provided data on their patients. Between 1998 and 2008, a total of
1138 patients were treated with TEVAR. In 25 patients (2.2%), the indication to treatment was an AEF and/or an ABF.
In 10 of these cases (40%), an associated open surgical procedure was also performed. Thirty-day mortality rate of
AEF/ABF endovascular repair was 28% (7 cases). No cases of paraplegia or stroke were observed. Mean follow-up was
22.6 months (range, 1-62). Actuarial survival at 2 years was 55%. Among the 18 initial survivors, five patients (28%)
underwent reintervention due to late TEVAR failure.
Conclusions: Stent grafting for AEF andABF represents a viable option in emergent and urgent settings. However, further
esophageal or bronchial repair is necessary in most cases. Despite less invasive attempts, mortality associated with these
conditions remains very high. (J Vasc Surg 2010;51:1195-202.)Aortoesophageal (AEF) and aortobronchial (ABF) fis-
tulae are uncommon and, in spite of appropriate and timely
treatment, highly lethal. AEF and ABF are most commonly
found in association with thoracic trauma, aortic aneu-
rysms, ruptured penetrating aortic ulcers, esophageal or
bronchogenic malignancies, and as a complication of tho-
racic surgery, including aortic surgery in up to 1.7% of
cases.1,2
Conventional treatment entails open surgical repair of
the thoracic aorta associated with esophageal or tracheo-
bronchial reconstruction. Mortality rates of open surgery
are primarily due to hemorrhagic and septic complications,
with rates reaching 61% in case of primary etiology and 78%
in case of secondary fistulae.3,4 Although several alternative
strategies have been reported in the literature, including
extra-anatomic bypass5 and in situ repair with cryopre-
served homograft,6 there is a lack of consensus concerning
the optimal treatment of AEF and ABF.
Thoracic endovascular aortic repair (TEVAR) has been
proposed as an alternative strategy to surgical manage-
ment.7-9 Although less invasive, this technique presents
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doi:10.1016/j.jvs.2009.10.130important limitations in treating AEF and ABF, mainly the
high risk of graft contamination. Several authors proposed
a variety of combinations of TEVAR with surgical aortic
repair, esophageal stent grafting, tracheobronchial or esopha-
geal reconstruction, mediastinal drainage, or even endoscopic
use of fibrin glue at the level of the fistula.10-12
However, relatively little is known about results of
TEVAR in the treatment of AEF and ABF. This is due to
the rarity of these conditions, the relatively recent clinical
introduction of endovascular techniques, and a lack of large
surveys in the literature.
The aim of this study is to report initial and midterm
results of TEVAR for AEF/ABF through a national survey
conducted in Italy.
METHODS
We conducted a cross-sectional survey on voluntary
basis among Italian universities and hospital centers with a
thoracic endovascular program. We developed a text
document-based survey in a collaborative effort between
several vascular surgeons. The survey was distributed in
November 2007 by e-mail to the medical directors of
Italian departments of vascular surgery or cardiothoracic
surgery with an acknowledged experience in thoracic aorta
stent grafting. Centers performing TEVAR on a regular
basis, even when lacking direct experience of AEF/ABF
treatment, were invited to participate. Accompanying the
questionnaire was a letter explaining the aims of the study
and the compiling modalities. Each center that failed to
respond was contacted by telephone or solicited by e-mail.
The survey ended in December 2008. Participating centers
were requested to provide data collected between 1998 and
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provided.
The questionnaire had three sections: section 1 con-
sisted of 26 items and inquired about the total number of
endovascular procedures performed on the thoracic aorta.
Section 2 aimed to determine the results of endovascular
repair of an established AEF or ABF. This section consisted
of 53 items, inquiring about patient demographics, preop-
erative risk factors, etiology of fistulae (Table I), clinical
features at presentation, preoperative imaging, blood cul-
tures (Table II), modality of treatment, endovascular pro-
cedure details, device characteristics (Table III), adjunctive
maneuvers, technical success, 30-day mortality and compli-
cations, secondary procedures, and mortality at follow-up.
Section 3 aimed to determine the rate of AEF/ABF as
postoperative complications after TEVAR. Although data
from Section 3 were collected within the same investiga-
tion, they pertain to different patients with different pathol-
ogies and will be reported in a separate publication.
Demographics and preoperative risk factors, including
coronary artery disease, pulmonary disease, and renal failure
were defined as previously reported.13 Anatomic location
of the proximal landing zone was defined according to the
“aortic arch map” proposed by Ishimaru (0 to 4).14 Results
of TEVAR were described according to the reporting stan-
dards for endovascular aortic aneurysm repair.15 Renal
dysfunction was defined as a rise in serum creatinine ex-
ceeding the baseline value by 30% and surpassing an abso-
lute level of 2.0 mg/dL. Myocardial infarction was sug-
Table I. TEVAR for AEF/ABF: patient demographics
Characteristics No. patients (%)
Overall 25 (100)
Age (mean  SD) 66.4  18.8
Gender (male) 17 (68)
Coronary artery disease 11 (44)
Diabetes mellitus 4 (16)
Hypertension 19 (76)
Cerebrovascular disease 3 (12)
Pulmonary disease 14 (56)
Renal failure 2 (8)
Smoking 5 (20)
ASA class
1 1 (4)
2 1 (4)
3 9 (36)
4 13 (52)
5 1 (4)
Etiology of the fistula
Primary/unknown 4 (16)
Atherosclerotic aneurysm 6 (24)
Penetrating ulcer/intramural hematoma 4 (16)
Chronic dissection 1 (4)
Foreign body/caustic ingestion 2 (8)
Esophageal cancer 1 (4)
Previous aortic open repair 4 (16)
Previous aortic endovascular repair 3 (12)
ASA,American Society of Anesthesiologists; TEVAR, thoracic endovascular
aortic repair; AEF, aortoesophageal fistulae; ABF, aortobronchial fistulae.gested by electrocardiographic changes and confirmed byelevation of cardiac enzymes, regardless of symptoms. Re-
spiratory failure was defined as ventilator dependence
of 72 hours, the need for postoperative reintubation,
clinical data or culture confirmation of pneumonia, or the
need for tracheostomy.
Patients were followed up according to the protocol
of each institution. Follow-up always included a thoracic
contrast-enhanced computed tomography (CT) or mag-
netic resonance (MR) imaging and an outpatient clinical
evaluation.
Preoperative and intraoperative variables of interest
were tested for significant association with the principal
outcomes using Fisher’s exact test or 2 test for categorical
data and unpaired t test or Mann-Whitney test for contin-
uous data, as appropriate. Actuarial survival was computed
according to the Kaplan-Meier log-rank method. All anal-
yses were run using SAS 8.02 software (SAS Institute Inc,
Cary, NC).
RESULTS
Among 39 contacted centers, 17 departments of vas-
cular surgery or cardiothoracic surgery, including that of
the authors, agreed to participate and provided patient
data.
Overall, 1138 patients were treated by TEVAR be-
tween 1998 and 2008. Ten of 11 centers (91%) with a
TEVAR experience exceeding 30 procedures reported at
least one case of AEF/ABF treated, whereas only one out of
six centers (17%) with a TEVAR experience of less than 30
procedures reported one case of AEF/ABF treated endo-
vascularly.
Twenty-five patients underwent TEVAR for an estab-
lished aortoesophageal or aortobronchial fistula. The fistula
involved the esophagus in 14 cases and the left bronchial
tree in 12 cases, with one patient presenting concomitant
esophageal and bronchial involvement. Patients’ demo-
graphics and preoperative risk factors are listed in Table I.
Symptoms at presentation and diagnostic studies performed
at admission are reported in Table II. The interval between the
first reported episode of hematemesis/hemoptysis and the
final diagnosis of AEF/ABF ranged from 2 hours to 6
months. CT scan performed at admission showed clear signs
of aortic infection or fistulization in all ABF patients and in
13/14 (93%) AEF patients (Fig 1). In two cases of ABF, the
diagnosis was confirmed by transesophageal echocardiogra-
phy, showing a penetrating ulcer of the descending thoracic
aorta and the proximity to the left lower segment bron-
chus.16 In retrospect, several participating surgeons stated
that there were suggestive symptoms of the fistula prior to
hospitalization, however, imaging studies often failed to
show a definitive fistulous tract. Blood cultures were posi-
tive in only five cases (20%) at admission. Isolated micro-
organisms included Escherichia coli, Klebsiella, Salmonella,
Streptococcus, and Corynebacterium species.
After establishing the diagnosis of AEF or ABF, all
procedures were performed as soon as possible, under
general anesthesia, in an operating room equipped for
prompt open surgical conversion. Stent grafts employed are
; ABF
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was 34.6  6.2 mm. A mean number of 1.1  0.3 devices
per patient were implanted. The mean aortic length cov-
ered was 140.9  45.4 mm.
Proximal landing zone was classified as “zone 1” in 2
patients, “zone 2” in 3 patients, “zone 3” in 10 patients,
and “zone 4” in 10 patients. Debranching of supra-aortic
vessels was performed for “zone 1” cases by means of
right-to-left carotid bypass. Selective revascularization of
the left subclavian artery (LSA) was performed in one
“zone 1” patient, a 36-year-old left-handed worker, and in
one “zone 2” patient, an 89-year-old male with previous
coronary artery bypass grafting using the left internal tho-
racic artery. Cerebrospinal fluid (CSF) drainage was insti-
tuted preoperatively in four hemodynamically stable pa-
tients (16%) with the aortic lesion to be covered involving
critical intercostal arteries (T8 to L2), requiring the cover-
age of a long descending thoracic aortic segment (20 cm)
or patients with previous abdominal/thoracoabdominal
aortic repair.
Mean duration of the operation was 159  185 min,
Table II. Clinical features at presentation and preoperativ
compared to patients who received combined (endovascul
Variable
Overall
No. patients
(%)
Total patients 25 (100)
Symptoms at presentation
Hematemesis/hemoptysis 22 (88)
Fever 8 (32)
Shock 12 (48)
Thoracic pain 3 (12)
Dyspnea 2 (8)
Dysphagia 2 (8)
Melena 2 (8)
Diagnostic studies showing AEF/ABF
Computed tomography 24 (96)
Gastrointestinal/bronchial endoscopy 12 (48)
Esophagogram 3 (12)
Angiography 2 (8)
Transesophageal echocardiography 2 (8)
TEVAR, Thoracic endovascular aortic repair; AEF, aortoesophageal fistulae
aFisher’s exact test.
Table III. Stent grafts implanted
Stent graft (manufacturer)
No. of
patients
Endofit (Endomed Inc, Phoenix, Ariz) 3
Relay (Bolton Medical Inc, Sunrise, Fla) 3
TAG (WL Gore and Assoc, Flagstaff, Ariz) 4
Talent (AVE/Medtronic Inc, Santa Rosa, Calif) 6
Valiant (AVE/Medtronic Inc, Santa Rosa, Calif) 2
Zenith TX1 (William Cook Europe Aps,
Bjaeverskov, Denmark) 2
Zenith TX2 (William Cook Europe Aps,
Bjaeverskov, Denmark) 5with a mean estimated blood loss of 517  470 mL.Ballooning of the stent graft was performed selectively in
seven cases (28%). One adjunctive endovascular procedure
was reported in a patient treated for ABF caused by an
atherosclerotic aneurysm, who underwent positioning of a
proximal cuff for type I endoleak 48 hours after the
primary endovascular operation. Concomitant or post-
poned planned adjunctive surgical procedures, other
than supra-aortic vessels debranching, were performed
in 10 patients (40%), including 5 esophageal resections
and/or reconstructions, 2 cervical esophagostomies, 2 je-
junostomies, 1 esophageal stenting, 1 pneumonectomy,
and 3 cases of thoracic or mediastinal drainage. Both pa-
tients presenting with a fistula due to foreign body or
caustic ingestion were treated by means of TEVAR with
early simple esophageal repair.
Assisted primary technical success was 100%. No intra-
operative deaths were recorded. Thirty-day mortality was
28% (7/25) due to multiple organ failure (n  4), respira-
tory failure (n  2), and myocardial infarction (n  1).
Overall 30-day morbidity was 56% (14/25). No cases of
paraplegia, paraparesis, or stroke were observed. Postoper-
ative complications included acute renal dysfunction in five
patients (20%), respiratory failure in 13 patients (52%), and
acute myocardial infarction in two patients (8%).
Mean follow-up was 22.6  21.8 months (range,
1-62). Actuarial survival at 2 years was 54.7%. Among the
18 initial survivors, six patients (33%) suffered from recur-
rent sepsis and/or hemorrhagic complications, resulting in
all cases in death or reintervention. Four patients died
during observation at follow-up, for an overall mortality at
follow-up of 44% (11/25). A 76-year-old female who
underwent TEVAR for a primary ABF with an uneventful
postoperative course, died 35 months later due to hemor-
rhagic shock of unknown origin. A 72-year-old male sub-
gnostic studies in patients treated with TEVAR alone
d surgical) treatment
TEVAR alone
No. patients
(%)
Combined
No. patients
(%)
P
valuea
15 (60) 10 (40)
14 (93) 8 (80) .543
3 (20) 5 (50) .194
4 (27) 8 (80) .015
2 (13) 1 (10) 1.0
0 (0) 2 (20) .150
1 (7) 1 (10) 1.0
1 (7) 1 (10) 1.0
15 (100) 9 (90) .400
6 (40) 6 (60) .428
1 (7) 2 (20) .543
1 (7) 1 (10) 1.0
0 (0) 2 (20) .150
, aortobronchial fistulae.e dia
ar anmitted to emergent TEVAR for a ruptured aneurysm caus-
ovasc
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hemorrhagic shock. He underwent extra-anatomic bypass
arising from the ascending aorta (“ventral aorta”), thoracic
stent graft removal, ligation of the arch and of the diaphrag-
matic aorta, and esophageal simple repair. He died within a
few hours from multiorgan failure. A 16-year-old female
submitted to TEVAR for an AEF following previous open
surgery for aortic coarctation, underwent multiple reinter-
ventions during the next 15 months, including esophageal
reconstruction with colonic interposition and aortic recon-
struction with cryopreserved homografts under hypother-
mic circulatory arrest. She died 8 months after the last
operation due to septic complications. Finally, a 71-year-
old female submitted to “zone 4” TEVAR for a primary
AEF, followed by the repair of the esophagus via right
thoracotomy, presented 3 months later with evidence of
bleeding at the level of the aortic proximal neck. She
underwent positioning of a proximal stent graft placed
below the origin of the LSA, but she died perioperatively
from multiorgan failure.
Overall, five patients (28%) underwent reintervention
due to late TEVAR failure, with a mean interval from
primary TEVAR of 5.6  5.4 months. Three patients
(reported above) died. Of the two survivors, one was a
61-year-old male submitted to TEVAR and esophageal
stent grafting for a secondary AEF following previous tho-
racoabdominal aortic repair.11He presented 3months later
with septic shock and was submitted to esophageal stent
graft removal via right thoracotomy, followed by esopha-
geal reconstruction with gastric interposition. He is alive
and well at 6 months of follow-up. The other patient was a
58-year-old female submitted to emergent TEVAR for a
posttraumatic concomitant AEF and ABF. She underwent
multiple reinterventions for recurrent bleeding and persis-
Fig 1. A, Preoperative computed tomography (CT) sc
aorta with fissurated thrombus. Esophageal compression
Postoperative CT scan after successful endovascular exclu
repaired via right thoracotomy 6 days after thoracic endtent sepsis, including re-TEVAR, esophageal repair withgastric interposition, left inferior pulmonary lobectomy,
and in situ reconstruction of the descending thoracic aorta
using bovine pericardium graft, under hypothermic circu-
latory arrest with antegrade cerebral perfusion. The patient
is alive and well at 30 months of follow-up.
No significant differences in terms of 30-day mortality
and overall mortality at follow-up were found between AEF
and ABF. However, duration of the procedure and intra-
operative blood loss were higher in the ABF group (235
234 min vs 94  66 min, P  .026; and 754  512 mL vs
392 286mL, P .039, respectively). Patients presenting
with shock were significantly younger than stable patients
(58.5  21.0 years vs 73.6  13.5 years; P  .026) and
were more frequently affected by AEF (77% vs 31%; P 
.047). Early and late mortality were similar in both groups
(25% vs 31%, P  1.0, and 33% vs 11%, P  .576, respec-
tively). Positive micro-organism findings in the blood cul-
tures were not associated with an increased overall mortal-
ity (2/5 patients died, one soon after TEVAR, and one
after multiple reoperations for recurrent sepsis).
There was no statistically significant difference in early
and late mortality between patients treated for primary and
secondary fistulae (22% vs 43%, P .355; and 33% vs 71%,
P  .177, respectively). However, patients with secondary
AEF/ABF presented with preoperative fever more often
than patients with primary fistulae (71% vs 20%, P .017).
Patients treated for a fistula due to foreign body or caustic
ingestion had both a postoperative uneventful course and
are alive and well at 48 and 7 months of follow-up, respec-
tively. No differences in operative variables and outcome
were identified concerning type of stent graft used or
manufacturer.
Patients who underwent TEVAR alone, without any
scheduled (concomitant or postponed) procedure were
owing a saccular aneurysm of the descending thoracic
wall thickening are evident on axial images (arrows). B,
of the aortic aneurysm. Esophageal defect was surgically
ular aortic repair (TEVAR).an sh
and
sionoverall comparable in terms of clinical features at presenta-
nt (K
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sisting of TEVAR associated with or followed by a sched-
uled esophageal or bronchial procedure, except for pre-
operative shock that was significantly more frequent in the
combined group (P .015, Table II). Patients treated with
TEVAR alone had a 30-daymortality of 40% (6/15) and an
overall mortality at follow-up of 53% (8/15). A better
outcome was recorded in patients who received combined
treatment (Fig 2), with a 30-day mortality of 10% (1/10)
and an overall mortality at follow-up of 30% (3/10). These
differences, however, did not reach statistical significance
(P  .179 and P  .414, respectively; Kaplan-Meier log-
rank test, P  .373).
DISCUSSION
Although AEF and ABF are believed to be extremely
uncommon, we found that this pathology was the indica-
tion in 2.2% of all TEVAR procedures performed from
1998 to 2008. Furthermore, the survey showed that most
centers performing more than 30 TEVAR procedures re-
ported at least one case of AEF/ABF endovascular treat-
ment. In the English literature, however, a relatively low
number of TEVAR for AEF/ABF is published to date,
consisting primarily of single case reports or small case
series with less than 12 patients.17 In addition, most large
international TEVAR trials do not include or mention this
specific pathology18-21 due to the important differences in
treatment modalities and results compared with aneurysms.
This may account for a considerable underestimation of the
problem.
Since AEF and ABF were first described by Dubrueil in
Fig 2. Survival by surgical manageme1818 and by Girardet in 1914, respectively,22,23 they areusually considered as two separate clinical entities. Never-
theless, they present many similar features in terms of
etiology, pathogenesis, presentation, and natural history,
and they occasionally occur together.24 In our study, no
significant differences in terms of perioperative and late
mortality were observed between AEF and ABF. The endo-
vascular procedure in case of ABF presented with increased
procedural times and blood loss. A possible explanation could
be that ABF are usually located more “proximally” compared
with AEF, resulting in more complex procedures. Consis-
tently, both “zone 1” and “zone 2” patients who required
LSA revascularization belonged to the ABF group, and this
may have contributed to increase the mean procedure dura-
tion and blood loss value.
If left untreated, both AEF and ABF are uniformly
fatal. In a review of AEF, Coselli and Crawford reported
that more of 60% of patients presenting with a herald
gastrointestinal bleed die within 6 hours.25 Thus, surgical
management must be immediate and must include hemo-
stasis and prevention of septic complications. In this survey,
nearly 90% of patients presented with hematemesis or he-
moptysis, and half of them were already in shock.
CT scan is the first imaging study performed in most
cases, as it is fast and easy to carry out in emergency
conditions. Although a CT scan rarely allows detecting a
fistulous tract, in this survey, suggestive signs of AEF/ABF
were present in most patients, including air bubbles into
the thrombus, periaortic fluid collection, esophageal or
bronchial wall thickening, and lung consolidation. Endos-
copy is known to be the most sensitive and specific method
for the diagnosis of AEF/ABF26 but often requires seda-
aplan-Meier log rank test, P  .373).tion and entails the risk of dislodging clots during progress
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found that transesophageal echocardiography may help to
confirm the presence of an ABF in selected cases.
Surgical repair is most commonly performed via a left
posterolateral thoracotomy, with simple cross-clamping of
the descending thoracic aorta. However, this maneuver
entails the risk of spinal cord and visceral ischemia, and
cardiopulmonary bypass may be required.Moreover, access
to the aorta may be particularly demanding due to dense
adhesions in patients with previous thoracic interven-
tions, as is the case of secondary fistulae, with a high risk
of adjacent organ lesions and significant blood loss. Direct
aortic suture or patch angioplasty are rarely employed and
are most often used in the treatment of small lesions asso-
ciated with foreign body ingestion.28 For larger lesions,
aortic replacement is usually required. In situ reconstruc-
tion with prosthetic bypass has been successfully performed
in the past29 but carries the potential for graft infection and
new fistulization. Cryopreserved homografts represent a
viable option for in situ aortic reconstruction,6 although
they are susceptible to infection as well, and long-term
secondary degeneration has been described.30 Extra-
anatomic bypass arising from the ascending aorta (ventral
aorta) reduces the risk of graft infection5 but must be
performed as a primary procedure, requires additional ster-
notomy extending to an upper laparotomy, and is often
unfeasible due to fistula hemorrhage. Moreover, it carries
the risk of aortic stump infection with potential long-term
complications.
In addition to repairing the aorta, the esophageal or
bronchial defect should be addressed. A small esophageal
defect may be treated by direct repair, whereas patients with
a larger esophageal defect may undergo esophageal recon-
struction with gastric or colonic interposition.31 The repair
of the bronchus in cases of ABFmay entail primary repair or
resection and anastomosis with reinforcement usingmuscle
flaps or pedicled omental flaps.32 Other options include
lobectomy or pneumonectomy.
Successful use of stent grafts in patients with aortoduo-
denal and ilioureteral fistulae have been reported in the last
decade.33,34 Treatment of a fistula between the thoracic
aorta and an adjacent organ by means of TEVAR was first
reported in 1996 by Chuter et al35 and in the same year by
Campagna et al.36 Subsequently, several cases were pub-
lished describing the feasibility of endovascular treatment
of AEF and ABF.7-12 Since endovascular treatment is sim-
pler, faster, and safer than open surgery in unstable patients,
TEVAR is considered by most authors as the first line
treatment to obtain immediate control of aortic bleeding.
In the overtly moribund patient, TEVAR has been pro-
posed as the most appropriate definitive strategy, as a
palliative procedure. Conversely, in good surgical candi-
dates, coverage of the aortic lesion, alongwith an aggressive
antibiotic therapy, may be used to achieve an improvement
in the patient’s general conditions, serving as a “bridge” to
open surgical treatment of the aortic and/or esophageal/
bronchial defect. Following successful TEVAR, there is no
general consensus concerning the need for planned stagedsurgical intervention, in the absence of clear signs of rein-
fection or bleeding.
In this series, both early and late mortality was in-
creased in cases of TEVAR alone management compared
with a combined (endovascular and surgical) approach. Of
the 15 patients submitted to TEVAR alone, eight patients
died at follow-up (53%). Six patients died within 30 days
from TEVAR (40%), one patient died 35 months later due
to hemorrhagic shock of unknown origin, and the last
patient presented after 5 months with fever and hemor-
rhagic shock, underwent thoracic stent graft removal and
extra-anastomic bypass but died within a few hours from
multiorgan failure. Of the 10 patients submitted to com-
bined treatment, overall three patients died at follow-up
(30%), and only one patient died within 30 days (10%). The
difference in early and late outcome, however, did not
reach statistical significance, possibly due to the small sam-
ple size. In addition, potential confounders are to be con-
sidered when comparing these two groups, mainly the
eventuality that the TEVAR alone group may also include
patients that would have been candidates to staged surgical
repair but who died before surgery could be scheduled.
Although clear limitations of the TEVAR alone strat-
egy include the risk of reinfection and septic complica-
tion, due to the inability to debride or drain the medias-
tinum, there has been some success in the literature with
this approach.37,38 Some authors suggest considering
TEVAR as a potential definitive treatment in patients at
high risk for complications with open surgical repair who
showed no clinical or imaging evidence of infection
(fever, leukocytosis, air or fluid collections on CT).39
However, in addition to the currently reported series,
poor late results of TEVAR alone strategies are reported
in most cases due to infectious complications or recur-
rent fatal bleeding.7,30,40,41
The evidence emerging from these results is not strong
enough to justify changes in clinical practice. It is clear,
however, that TEVAR alone does not provide complete
and durable cure for AEF and ABF, and that these patients
need to be followed closely to evaluate the opportunity and
the appropriate timing for a secondary surgical procedure.
Also, treatment strategy and time interval between TEVAR
and additional surgical procedures are individualized, ac-
cording to patient conditions and the grade of sepsis.
Patients presenting with fistulae from a foreign body or
caustic ingestion are typically young and healthy and may
have an uncomplicated course with a low risk of reinfec-
tion.42 On the contrary, patients with secondary AEF or
ABF are usually elderly and affected by several comorbidi-
ties. In this survey, secondary fistulae were associated with a
high prevalence of preoperative fever, and this may reflect a
severe grade of sepsis due to the presence of an additional
infected aortic surgical graft. In these cases, a delayed
staged surgical procedure following TEVAR is often pre-
ferred to achieve an improved general clinical condition and
recovery from sepsis.
Another concern regards the fate of the stent graft
during long-term follow-up. Although we did not record
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known complications of TEVAR and were previously re-
ported in a case of AEF treatment.38 Recurrent sepsis
and/or hemorrhagic-related complications were ob-
served in this series in around one-third of cases at a
mean follow-up of approximately 2 years. Although re-
infection is usually attributed to stent graft contamination,
the stent graft itself has the potential to erode into adjacent
organs, causing a new fistulization.43 Prolonged antibiotic
therapy and life-long surveillance is crucial in these patients,
regardless of symptoms or clinical signs of sepsis.
In conclusion, the incidence of AEF and ABF is
probably underestimated, and centers that regularly per-
form thoracic aortic surgery will eventually deal with this
complex pathology. TEVAR has a predominant role in
controlling the massive hemorrhage associated with AEF
and ABF in the usual setting of sepsis and medical comor-
bidities. In cases of minimal local infection, further treat-
ment may be unnecessary. In the other cases, a definitive
esophageal or bronchial repair is indicated after stabili-
zation.
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Primary and secondary aortoesophageal and aortobronchial
fistulas are uniformly fatal if untreated, remain a formidable surgi-
cal problem, and carry high operative mortality in older, high-risk
patients with hemorrhagic shock or sepsis, and in those with
secondary communications between the aorta and/or graft and
the aerodigestive tract. This article represents one of the larger
series, which define the role for thoracic endovascular aortic repair
(TEVAR) for these problems. Clearly, TEVAR is becoming the
initial primary treatment, but the importance of this article is the
analysis of patient outcomes in the group treated with TEVAR
alone compared with the group who had TEVAR followed later by
aortic reconstruction and treatment of the esophageal and bron-
chial defects. The authors question the utility of TEVAR as the
only mode of therapy because of a higher 30-day and midterm
mortality in this group compared with patients treated with a
combined approach.
Based on their data, TEVAR as sole definitive treatment
should be reserved for patients with small aortobronchial commu-
nications and no CT evidence of mediastinal infection at initial
presentation or during follow up. Since patients in shock with
primary or secondary aortoesophageal fistulas had a much highercombined approach to treat them. The choice of conduit and route
for aortic reconstruction, and the specific treatment of the fistula
are dependent on patient age and comorbid conditions, the sever-
ity of infection, the location and type of fistula, and whether a
thoracic graft is already in place. Definitive treatment should follow
the precepts used to treat aortic graft-enteric erosions or fistulas in
the abdomen. Choices for aortic reconstruction include ascending
aorta to upper abdominal prosthetic bypass; or in situ replacement
with antibiotic-soaked prosthetic or homografts. The authors sug-
gest early resection of the involved segment of esophagus or lung
in patients with mediastinal sepsis. Vascularized pericardial or
pleural flaps, serratus muscle, or omentum can be used to cover the
graft or the aortic stumps. What seems crucial to improve patient
outcomes, not addressed in detail in this report, is identification of
specific factors that influence timing of the definitive open surgical
repair, and the role for suppressive antibiotics. Similar to the
treatment of abdominal aortic graft infection, one could argue for
a 6 to 8- week course of broad spectrum IV antibiotics in the
interval between TEVAR and definitive repair, followed by lifelong
oral antibiotic suppression for those with aortoesophageal fistulas,
extensive mediastinal contamination, and in situ prosthetic aortic
grafts.
